Picture of Divi's Laboratories logo

DIVISLAB — Divi's Laboratories News Story

0.000.00%
in flag iconLast trade - 00:00
HealthcareConservativeLarge CapHigh Flyer

India's Divi's Lab gains again on Q3 print; analysts flag good execution, key risk

** Divi's Laboratories  DIVI.NS  rises ~5% in second session
of gains post Q3 results
    ** Co's custom synthesis segment grows 45% y/y in Q3
    ** BOB Capital upgrades to "hold" from "sell", citing co's
effective opportunity utilisation in the fast growing segment
    ** Jefferies retains "hold" despite custom synthesis
improving product mix and profit
    ** Says co needs to overcome high rev concentration of key
heart failure drug the patent for which will expire in 2026
    ** Co working on glucose stabilising hormone GLP-1
manufacturing process to diversify
    ** Systematix Equities says DIVI seeing interest in GLPs
from several MNCs; has strong position due to backward
integration
    ** But retains "sell" on rich stock valuation
    ** DIVI rated "hold" on avg; mean PT of 5,427 rupees is
12.2% downside to current price of 6,185.7 rupees
    ** Stock up 66% YTD

 (Reporting by Ananta Agarwal in Bengaluru)
 ((Ananta.Agarwal@thomsonreuters.com))

Recent news on Divi's Laboratories

See all news